J. Fay

发表

Pharmacological Properties of MK-3207, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist

J. Vacca, C. Regan, Y. S. Tang, 2010, Journal of Pharmacology and Experimental Therapeutics.

Pharmacological Characterization of MK-0974 [N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of

A. W. Shaw, J. Vacca, Victor K. Johnston, 2008, Journal of Pharmacology and Experimental Therapeutics.

Active CGRP Receptor Antagonist for the Treatment of Migraine

A. W. Shaw, J. Vacca, S. Graham, 2007 .

Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.

P. D. Cook, J. Tomassini, M. Maccoss, 2004, Journal of medicinal chemistry.

A Phenotypic Screen Identifies Potent DPP9 Inhibitors Capable of Killing HIV-1 Infected Cells.

W. Shipe, I. Cornella-Taracido, An Chi, 2022, ACS chemical biology.

Novel CGRP receptor antagonists from central amide replacements causing a reversal of preferred chirality.

J. Vacca, H. Selnick, R. Bednar, 2010, Bioorganic & medicinal chemistry letters.

A 7-Deaza-Adenosine Analog Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic Properties

Giovanni Migliaccio, D. Hazuda, J. Tomassini, 2004, Antimicrobial Agents and Chemotherapy.

Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists.

A. Dilella, T. Mcdonald, D. Reiss, 2011, ACS chemical neuroscience.

Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group.

W. Shipe, H. Su, J. Gesell, 2016, ACS medicinal chemistry letters.

Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors.

Tao Ji, William Morris, M Katharine Holloway, 2017, ACS medicinal chemistry letters.

Potent benzimidazolone-based CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, Victor K. Johnston, 2008, Bioorganic & medicinal chemistry letters.

Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, J. Hochman, 2006, Bioorganic & medicinal chemistry letters.

The discovery of highly potent CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, Victor K. Johnston, 2009, Bioorganic & medicinal chemistry letters.

An in vitro Flaviviridae replicase system capable of authentic RNA replication.

J. Tomassini, L. Gan, R. Lafemina, 2003, Virology.

Identification of a Key Determinant of Hepatitis C Virus Cell Culture Adaptation in Domain II of NS3 Helicase*

D. Graham, G. Migliaccio, Amy L Simcoe, 2003, The Journal of Biological Chemistry.

Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead.

J. Vacca, P. Kunapuli, S. Graham, 2006, Bioorganic & medicinal chemistry letters.

Enhanced Factor VIIIa Stability of A2 Domain Interface Variants Results from an Increased Affinity for the A2 Subunit

Philip, H. Wakabayashi, M. Monaghan, 2015 .

The identification of a novel lead class for phosphodiesterase 2 inhibition by fragment-based drug design.

Deping Wang, Sujata Sharma, W. Shipe, 2017, Bioorganic & medicinal chemistry letters.

Structural optimization of cyclic sulfonamide based novel HIV-1 protease inhibitors to picomolar affinities guided by X-ray crystallographic analysis

P. Orth, S. Carroll, C. Strickland, 2014 .

Potent targeted activator of cell kill molecules eliminate cells expressing HIV-1

Min Xu, D. Hazuda, M. Bukhtiyarova, 2023, Science Translational Medicine.

Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility.

J. Vacca, H. Selnick, I. M. Bell, 2009, Bioorganic & medicinal chemistry letters.

Identification of potent, highly constrained CGRP receptor antagonists.

Steven S. Sharik, Cory R. Theberge, J. Vacca, 2010, Bioorganic & medicinal chemistry letters.

Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist.

J. Vacca, C. Regan, T. Prueksaritanont, 2010, ACS medicinal chemistry letters.

The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, Victor K. Johnston, 2009, Bioorganic & medicinal chemistry letters.